TIPE3 in Cancer: A Multifaceted Regulator of Tumorigenesis, Therapeutic Resistance, and Clinical Outcomes.

TIPE3, encoded by the human gene, is a member of the TNFAIP8 family of lipid second-messenger transfer proteins that connects phosphoinositide signaling with cancer progression, therapeutic resistance, and clinical outcomes. Unlike other TIPE-family members primarily involved in immune regulation or apoptosis, TIPE3 directly transfers phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-trisphosphate (PIP3) and modulates the PI3K/AKT, MEK/ERK, Wnt/β-catenin, NF-κB, Hedgehog, and mitochondrial stress pathways. Current evidence indicates that TIPE3 generally facilitates tumor growth, invasion, immune remodeling, autophagy, and platinum resistance across various malignancies, including lung, breast, pancreatic, gastric, colorectal, ovarian, cervical cancers, glioblastoma, and acute myeloid leukemia, whereas it may exhibit tumor-suppressive effects in specific contexts, such as head and neck squamous cell carcinoma. This review emphasizes three key concepts: pan-cancer functional duality, localization- and epigenetic-dependent regulation, and TIPE3-guided therapeutic stratification. We also examine conflicting findings, particularly in colorectal cancer, where disparities in mRNA versus protein assessment, tumor composition, immune contexture, subcellular localization, and treatment exposure may contribute to inconsistent prognostic associations. Finally, we propose a translational framework that integrates standardized detection, localization-aware pathology, multi-omics profiling, organoid and patient-derived xenograft validation, AI-assisted inhibitor discovery, RNA-based delivery, and rational combination therapy. Although no TIPE3-targeted therapies have yet reached clinical application, emerging mechanistic and drug discovery studies underscore TIPE3's potential as a valuable biomarker and therapeutic target in precision oncology.